BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

LD-2 disclosure · 1st Quarter - Report

IMPRIMIS PHARMACEUTICALS, INC.

via MORGAN, LEWIS & BOCKIUS, LLP

1st Quarter (Jan 1 - Mar 31) · 2018Posted Apr 19, 2018Filing document ↗LDA record ↗

Income$30Kfee reported

Client

Name: IMPRIMIS PHARMACEUTICALS, INC.
Description: Pharmaceutical Company
Location: California · United States of America

Registrant

Firm: MORGAN, LEWIS & BOCKIUS, LLP
Description: Law Firm
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medicare/Medicaid
Proposal for legislation to reduce prescription drug prices on proprietary compounded ophthalmic formulations.
LobbyistsCHRIS COX
TargetedSENATE · HOUSE OF REPRESENTATIVES

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.

IMPRIMIS PHARMACEUTICALS, INC. — Lobbying — Receipts Report